Literature DB >> 33146420

Transfusion support in COVID-19 patients: Impact on hospital blood component supply during the outbreak.

Kyra Velázquez-Kennedy1, Alejandro Luna1, Adrián Sánchez-Tornero1, Carlos Jiménez-Chillón1, Ana Jiménez-Martín1, Ana Vallés Carboneras1, María Tenorio1, Irene García García1, Francisco Javier López-Jiménez1, Gemma Moreno-Jiménez1.   

Abstract

BACKGROUND: During the COVID-19 outbreak, most hospitals deferred elective surgical procedures to allow space for the overwhelming number of COVID-19 patient admissions, expecting a decrease in routine blood component requirements. However, because transfusion support needs of COVID-19 patients are not well known, its impact on hospital blood supply is uncertain. The objective of this study was to assess the effect of the COVID-19 pandemic on transfusion demand. STUDY DESIGN AND METHODS: Transfusion records during the peak of the COVID-19 pandemic (March 1-April 30, 2020) were reviewed in our center to assess changes in blood requirements.
RESULTS: During this period 636 patients received a total of 2934 blood components, which reflects a 17.6% reduction in transfusion requirements with regard to the same period of 2019, and blood donations in Madrid dropped by 45%. The surgical blood demand decreased significantly during the outbreak (50.2%). Blood usage in the hematology and oncology departments remained unchanged, while the day ward demand halved, and intensive care unit transfusion needs increased by 116%. A total of 6.2% of all COVID inpatients required transfusion support. COVID-19 inpatients consumed 19% of all blood components, which counterbalanced the savings owed to the reduction in elective procedures.
CONCLUSION: Although only a minority of COVID-19 inpatients required transfusion, the expected reduction in transfusion needs caused by the lack of elective surgical procedures is partially offset by the large number of admitted patients during the peak of the pandemic. This fact must be taken into account when planning hospital blood supply.
© 2020 AABB.

Entities:  

Keywords:  COVID; blood transfusion service; management; outbreak; transfusion

Year:  2020        PMID: 33146420     DOI: 10.1111/trf.16171

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  6 in total

Review 1.  Management of Hematologic Malignancies in the Era of COVID-19 Pandemic: Pathogenetic Mechanisms, Impact of Obesity, Perspectives, and Challenges.

Authors:  Dimitrios Tsilingiris; Narjes Nasiri-Ansari; Nikolaos Spyrou; Faidon Magkos; Maria Dalamaga
Journal:  Cancers (Basel)       Date:  2022-05-19       Impact factor: 6.575

2.  Scalable production and complete biophysical characterization of poly(ethylene glycol) surface conjugated liposome encapsulated hemoglobin (PEG-LEH).

Authors:  Uddyalok Banerjee; Savannah Wolfe; Quintin O'Boyle; Clayton Cuddington; Andre F Palmer
Journal:  PLoS One       Date:  2022-07-08       Impact factor: 3.752

3.  We stand ready … Blood collection organizations and the COVID-19 pandemic.

Authors:  Hany Kamel
Journal:  Transfusion       Date:  2021-05       Impact factor: 3.157

4.  COVID-19 pandemic and blood transfusion services: The impact, response and preparedness experience of a tertiary care blood center in southern Karnataka, India.

Authors:  Dhivya Kandasamy; Shamee Shastry; Deepika Chenna; Ganesh Mohan
Journal:  Hematol Transfus Cell Ther       Date:  2021-12-16

5.  Positive Direct Antiglobulin Test in COVID-19 patients: decision-making process.

Authors:  Julien Cabo; Alice Brochier; Pascale Saussoy; Marie-Astrid van Dievoet; Lena Capirchio; Bénédicte Delire; Véronique Deneys
Journal:  Transfus Clin Biol       Date:  2021-06-07       Impact factor: 1.406

6.  Effect of the first year of COVID-19 pandemic on the collection and use of blood components in Colombia monitored through the national haemovigilance system.

Authors:  María-Isabel Bermúdez-Forero; Jonathan-Andrés Soto-Viáfara; Paula-Andrea Gardeazábal-Acuña; Diego-Alexander Anzola-Samudio; Michel-Andrés García-Otálora
Journal:  Transfus Med       Date:  2021-10-24       Impact factor: 2.057

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.